As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with ...
Manufacturing CAR T cell therapy—one of the most powerful weapons against certain blood cancers—has to date involved an elaborate process, through which doctors first extract a patient’s immune cells ...
A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...
SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patientsGlobal TENACITY-01 study reports 86% overall response ...
T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response ...
Under the agreement, Cellares will use its Cell Shuttle and Cell Q systems to automate TSC-101 manufacturing processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results